Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells

Invasion and Metastasis

Volumn 16, Issue 3, 1996, Pages 150-159

  Fishman, David A ^a   Bafetti, Lisa M ^a   Sharon Stack, M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Gelatinase; Invasion; Matrix metalloproteinase 2; Membrane type matrix metalloproteinase; Ovarian carcinoma

Indexed keywords

CONCANAVALIN A; ENZYME ACTIVATOR; ENZYME PRECURSOR; GELATINASE A; MATRIX METALLOPROTEINASE; MEMBRANE ENZYME; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; ASCITES FLUID; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME RELEASE; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; OVARY CARCINOMA;

CARCINOMA; COLLAGEN; CONCANAVALIN A; CULTURE MEDIA, CONDITIONED; DRUG COMBINATIONS; FEMALE; GELATINASES; HUMANS; IMMUNOHISTOCHEMISTRY; LAMININ; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; METALLOENDOPEPTIDASES; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PROTEOGLYCANS; TUMOR CELLS, CULTURED;

EID: 0030435159     PISSN: 02511789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Hoskins WJ: Prospective on ovarian cancer, J Cell Biochem 1995;(suppl 23):189-199.
2. Liotta LA, Rao N, Wewer UM: Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem 1986;55:1037-1057.
3. Niedbala MJ, Crickard K, Bernacki RJ: In vitro degradation of extracellular matrix by human ovarian carcinoma cells. Clin Exp Metastasis 1987;5:181-197.
4. Kanemoto T, Martin GR, Hamilton TC, Fridman R: Effects of synthetic peptides and protease inhibitors on the interaction of a human ovarian cancer cell line (NIH:OVCAR-3) with a reconstituted basement membrane. Invasion Metastasis 1991;11:84-92.
5. Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii T, Terao T: Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res 1992;52:3610-3614.
6. Moser TL, Young TN, Rodriguez GC, Pizzo SV, Bast RC, Stack MS: Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer 1994;56:552-559.
7. Young TN, Rodriguez GC, Moser TL, Bast RC, Pizzo SV, Stack MS: Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. Am J Obstet Gynecol 1994;170:1285-1296.
8. Young TN, Rodriguez GC, Rinehart AR, Bast RC, Pizzo SV, Stack MS: Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: Purification of matrix metalloproteinase-2. Gynecol Oncol 1996;62:89-99.
9. Woessner FJ: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-2154.
10. Mignatti P, Rifkin D: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993;73:161-195.
11. Autio-Harmainen H, Karttunen T, Hurskainen T, Hoyhtya M, Kauppila A, Tryggvason K: Expression of 72 kDa type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab Invest 1993;69:312-321.
12. Naylor MS, Stamp GW, Davies BD, Balkwill FR: Expression and activity of MMPs and their regulators in ovarian cancer. Int J Cancer 1994;58:50-56.
13. Afzal S, Lalani EN, Foulkes WD, Boyce B, Tickle S, Cardillo MR, Baker T, Pignatelli M, Stamp GWH: Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest 1996;74:406-421.
14. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993;53:2087-2091.
15. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994;370:61-65.
16. Takino T, Sato H, Shinagawa A, Seiki M: Identification of the second membrane-type matrix metalloproteinase gene from a human placenta cDNA library. J Biol Chem 1995;270:23013-23020.
17. Puente XS, Pendas AM, Llano E, Velasco G, Lopez-Otin C: Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res 1996;56:944-949.
18. Will H, Hinzmann B: cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential trans-membrane segment. Eur J Biochem 1995;231:602-608.
19. Ward RV, Atkinson SJ, Reynolds JJ, Murphy G: Cell surface-mediated activation of progelatinase A: Demonstration of the involvement of the C-terminal domain of progelatinase A in cell surface binding and activation of progelatinase A by primary fibroblasts. Biochem J 1994;304:263-269.
20. Yu M, Sato H, Seiki M, Thompson EW: Complex regulation of membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation by concanavalin A in MDA-MB-231 human breast cancer cells. Cancer Res 1995;55:3272-3277.
21. Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, Chambon P, Basset P: Membrane-type matrix metalloproteinase gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 1995;92:2730-2734.
22. Gilles C, Polette M, Piette J, Munaut C, Thompson EW, Birembaut P, Foidart JM: High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int J Cancer 1996;65:209-213.
23. Yamamoto M, Mohanam S, Sawaya R, Fuller GN, Seiki M, Sato H, Gokaslan ZL, Liotta LA, Nicolson GL, Rao JS: Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res 1996;56:384-392.
24. Rodriguez GC, Berchuck A, Whitaker RS, Schlossman D, Clarke-Pearson D, Bast RC Jr: Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. Am J Obstet Gynecol 1991;164:745-750.
25. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinomas. J Clin Invest 1981;68:1331-1337.
26. Boyer CM, Borowitz MJ, McCarty KS, Kinney RB, Everitt L, Dawson DV, Ring D, Bast RC Jr: Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells. Int J Cancer 1989;43:55-60.
27. Azzam HS, Thompson EW: Collagen-induced activation of the Mr 72,000 type TV collagenase in normal and malignant human fibro-blastoid cells. Cancer Res 1992;52:4540-4544.
28. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
29. Salvesen GS, Nagase H: Inhibition of proteolytic enzymes; in Benyon RJ, Bond JS (eds): Proteolytic Enzymes. A Practical Approach. Oxford, IRL, pp 83-104.
30. Moser TL, Pizzo SV, Bafetti LM, Fishman DA, Stack MS: Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the α2-β1 integrin. Int J Cancer 1996;67:695-701.
31. Matsudaira P: Sequence from picomole quantities of proteins electro-blotted onto polyvinylidene difluoride membranes. J Biol Chem 1987;262:10035-10038.
32. Young TN, Pizzo SV, Stack MS: A plasma membrane-associated component of ovarian adenocarcmoma cells enhances the catalytic efficiency of matrix metalloproteinase-2. J Biol Chem 1995;270:999-1002.
33. Karlan BY, Amin W, Band V, Zurawshi VR, Littlefield BA: Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro. Gynecol Oncol 1988;31:103-112.
34. Casslen B, Gustavsson B, Astedt B: Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumors. Eur J Cancer 1991;27:1445-1448.
35. Pedersen N, Schmitt M, Ronne E, Nicoletti MI, Hoyer-Hansen G, Conese M, Giavazzi R, Dano K, Kuhn W, Janicke F, Blasi F: A ligand-free soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 1993;92:2160-2167.
36. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72-kDa type IV collagenase. J Biol Chem 1995;270:5331-5338.
37. Emmert-Buck MR, Emonard HP, Corcoran ML, Krutzsch HC, Roidart JM, Stetler-Stevenson WG: Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex. FEES Lett 1995;364:28-32.
38. Imai K, Ohuchi E, Aoki T, Nomura H, Fujii Y, Sato H, Seiki M, Okada Y: Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2. Cancer Res 1996;56:2702-2710.